Solid Dispersions Having Stabilized Emulsion Particles Patent Application
Summary
USPTO published patent application US20260096994A1 for solid dispersion compositions containing active pharmaceutical ingredients and dispersion carriers. The application covers methods of dissolving API with carriers, combining with anti-solvent containing surfactant to form emulsions, and removing solvent to achieve predetermined particle size ranges. The application notably includes Compound (1) (zongertinib).
What changed
USPTO published patent application US20260096994A1 covering methods to prepare solid dispersion compositions comprising active pharmaceutical ingredients and dispersion carriers. The methods involve dissolving API with carrier in solvent, combining with anti-solvent containing surfactant to form emulsions, and removing solvent to generate compositions with predetermined mean particle size. The application covers compositions where API is amorphous and includes Compound (1) (zongertinib).
This patent application establishes prior art in solid dispersion drug delivery technology. Pharmaceutical manufacturers developing amorphous solid dispersions or nanoemulsion-based drug delivery systems should monitor this application as it may affect freedom-to-operate assessments for drug formulations using precipitation or anti-solvent methods to achieve controlled particle sizes.
What to do next
- Monitor for updates
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SOLID DISPERSIONS HAVING STABILIZED EMULSION PARTICLES
Application US20260096994A1 Kind: A1 Apr 09, 2026
Inventors
Michael BRAUN, Tao ZHANG
Abstract
Provided is a method to prepare a solid dispersion composition comprising an active pharmaceutical ingredient (API) and a pharmaceutically acceptable dispersion carrier, which includes (a) dissolving the API and the pharmaceutically acceptable dispersion carrier in a solvent to form a dissolved API/pharmaceutically acceptable dispersion carrier solution; and/or (b) combining the dissolved API/pharmaceutically acceptable dispersion carrier solution and an anti-solvent to form a combination, wherein the anti-solvent comprises a surfactant; and/or (c) mixing the combination to generate an emulsion with a predetermined mean particle size range; and/or (d) removing the solvent from the emulsion to generate the solid dispersion composition, wherein the solid dispersion composition has the predetermined mean particle size range. Preferably, the API in the solid dispersion composition is amorphous. Also provided is an emulsion and/or a solid dispersion composition comprising the API and a dispersion carrier. Also provided is a solid dispersion made by the methods of the invention. In embodiments, the present invention includes Compound (1), also known as zongertinib, and apparatus for continuous processing according to the methods disclosed herein.
CPC Classifications
A61K 9/2095 A61K 9/146 A61K 9/2077 A61K 31/519
Filing Date
2025-10-03
Application No.
19348878
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.